enzyme disorders

Graphic image of two hands shaking with employeesexecutives on the forearms of each shaking hand
Biotech

BioMarin inks $270M Inozyme buyout, bagging phase 3 prospect

BioMarin has followed through on its shift to external innovation, inking a deal to add a phase 3 enzyme replacement therapy to its pipeline.
Nick Paul Taylor May 16, 2025 8:46am
Motion blurs of people hurrying around an office

BioMarin's R&D head hopes pipeline of good ideas won't 'dry out'

Feb 21, 2025 7:00am
obesity drugs

Syntis launches with obesity pill to mimic gastric bypass

Jun 11, 2024 7:00am
Takeda

Takeda takes orphan drug to regulators after seeing phase 3 data

Jan 5, 2023 9:35am